Investigational Oral Medication AZD5462 Shows Promise in Improving Cardiac Function for Chronic Heart Failure Patients

The LUMINARA phase IIb trial, presented at ESC Congress 2026 and published in Circulation, found that the oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, particularly at the lowest dose for those with reduced ejection fraction. No safety concerns were noted, warranting further trials.